Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

NCT05225831 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

CD19+ and CD 22+ B-ALL

Interventions

BIOLOGICAL: Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
DRUG: Cyclophosphamide,Fludarabine

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]